# Colorectal Neoplasms FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/colorectal-neoplasms

> 10 upcoming FDA catalysts in colorectal Neoplasms: Tukysa (tucatinib, PFE) on Dec 2027 to Mar 2028 (topline data readout); RYBREVANT (amivantamab, JNJ) on Dec 2027 to Mar 2028 (topline data readout); RYBREVANT (amivantamab, JNJ) on December 2027 (primary completion); Tukysa (tucatinib, PFE) on December 2027 (primary completion); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 14, 2025 | [Lonsurf primary completion](https://sec-api.dev/pdufa/lonsurf) | BMY | Colorectal Neoplasms | withdrawn | "NCT05328908 (A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-14 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-08-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05328908)) |
| Dec 2027 to Mar 2028 | [Tukysa (tucatinib) topline data readout](https://sec-api.dev/pdufa/tucatinib) | PFE | Colorectal Neoplasms | scheduled | "NCT05253651 (A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05253651)) |
| Dec 2027 to Mar 2028 | [RYBREVANT (amivantamab) topline data readout](https://sec-api.dev/pdufa/amivantamab) | JNJ | Colorectal Neoplasms | scheduled | "NCT06750094 (A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750094)) |
| December 2027 | [RYBREVANT (amivantamab) primary completion](https://sec-api.dev/pdufa/amivantamab) | JNJ | Colorectal Neoplasms | scheduled | "NCT06750094 (A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750094)) |
| December 2027 | [Tukysa (tucatinib) primary completion](https://sec-api.dev/pdufa/tucatinib) | PFE | Colorectal Neoplasms | scheduled | "NCT05253651 (A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05253651)) |
| Sep to Dec 2028 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Colorectal Neoplasms | scheduled | "NCT05239741 (Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05239741)) |
| September 2028 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Colorectal Neoplasms | scheduled | "NCT05239741 (Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05239741)) |
| November 2028 | [Olomorasib primary completion](https://sec-api.dev/pdufa/olomorasib) | LLY | Colorectal Neoplasms | scheduled | "NCT07814417 (A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07814417)) |
| Nov 2028 to Feb 2029 | [Olomorasib topline data readout](https://sec-api.dev/pdufa/olomorasib) | LLY | Colorectal Neoplasms | scheduled | "NCT07814417 (A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07814417)) |
| Dec 2028 to Mar 2029 | [RYBREVANT (amivantamab) topline data readout](https://sec-api.dev/pdufa/amivantamab) | JNJ | Colorectal Neoplasms | scheduled | "NCT06662786 (A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06662786)) |
| December 2028 | [RYBREVANT (amivantamab) primary completion](https://sec-api.dev/pdufa/amivantamab) | JNJ | Colorectal Neoplasms | scheduled | "NCT06662786 (A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06662786)) |

## Drugs

- [Lonsurf](https://sec-api.dev/pdufa/lonsurf) (BMY)
- [Tukysa (tucatinib)](https://sec-api.dev/pdufa/tucatinib) (PFE)
- [RYBREVANT (amivantamab)](https://sec-api.dev/pdufa/amivantamab) (JNJ)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Olomorasib](https://sec-api.dev/pdufa/olomorasib) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/colorectal-neoplasms.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Colorectal Neoplasms FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/colorectal-neoplasms

```bibtex
@misc{secapidev_indications_colorectal_neoplasms_20261116,
  title        = {Colorectal Neoplasms FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/colorectal-neoplasms}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_colorectal_neoplasms_20261116","title":"Colorectal Neoplasms FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/colorectal-neoplasms","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
